A new, simple, precise, accurate and reproducible Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method for Simultaneous estimation of bulk and pharmaceutical formulations. Separation of Mirabegron was successfully achieve , C18, 250X4.6mm, 5µm or equivalent in an isocratic mode utilizing methanol water (70:30) at pH 5.0 Adjusted to OPA at a flow rate of 1.0ml/min and eluate was monitored at 243nm, with a retention time of 2.584 minutes for Mirabegron. The method was validated and the response was found to be linear in the drug concentration range of 50µg/ml to150 µg/ml for Mirabegron. The values of the correlation coefficient were found to 0.999for Mirabegron. The Limit of Detection(LOD) and Limit of Quantification (LOQ) for Mirabegron were found to be 0.149 and 0.498 res pectively. This method was found to be good percentage recovery were found to be 99 indicates that the proposed method is highly accurate. The specificity of the method shows good correlation between retention times of standard with the sample so, the method specifically determines the analyte in the sample without interference from excipients of tablet dosage forms. The method was extensively validated according to International Council for Harmonisation(ICH) guidelines for Linearity, Accuracy, Precision, Specificity and Robustness.
INTRODUCTION
The chemical name for Mirabegron is 2-(2-amino-1, 3 thiazol-4-yl)-N- [4-[2- [[(2R)-2-hydroxy-2phenylethyl]amino]ethyl]phenyl]acetamide having a molecular formula of C21H24N4O2S and a molecular weight of 396.509 g/mol.1 Mirabegron is a beta-3 adrenergic agonist that is used for treatment of overactive bladder syndrome.2-4 It has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury. Its primary use is in the treatment of overactive bladder.5 Mirabegron dose-dependently increased cyclic adenosine 3', 5'-monophosphate (cAMP) concentrations in bladder tissues isolated from rats and showed a potent relaxant effect in isolated rat and human bladder strips precontracted with carbachol at low contraction tonus. Recently, Mirabegron was shown to relax in vitro human and rabbit prostate smooth muscle through activation of β3 adrenoceptor. The same group also showed that Mirabegron encourages smooth muscle relaxation by α1 adrenergic receptor blockade.
Fig 1-chemical structure of Mirabegron
Mirabegron is highly soluble in water, sparingly soluble in methanol, and practically insoluble in methylene chloride. 6 Analytical method development and validation play important role in the discovery, development and manufacture of pharmaceuticals.7-8 A detailed literature survey reveals that only a few methods are reported previously to determine Mirabegron.
Flow Rate: 1.0 ml/min, Detection Wavelength:243 nm, Run time: 6 min, Injection volume: 20.0 μl.
Detection Wavelength by UV Spectroscopy:
The absorption maximum of MGN was determined using 10μg/ml working solution of MGN. The solution was prepared in mobile phase (Methanol 70:Water 30 at pH 5.0adjusted with OPA). The absorption spectrum or UV spectrum recorded for MGN was as shown in Figure 2 and the corresponding absorbance values were as illustrated in Table 1 . As shown in Table 1 , the MGN has showed absorbance at two different wavelength viz. 243 and 204nm. Out of the two wavelengths, the absorbance at 204nm was found to be 1.114 which found maximum of the two absorbances. Nevertheless, it is in the range of solvent cutoff for Methanol. As Methanol is component of the mobile phase, the other wavelength 243nm with absorbance of 0.773, although less than that at 204nm was selected for further analysis in order to avoid interferences of mobile Phase 
HPLC method development
The aqueous phase for the present method development was HPLC grade water. The aqueous phase is also consisting of 0.5% Triethylamine as an ion pairing reagent. The pH of the aqueous phase was adjusted with Ortho phosphoric acid and maintained at pH 5.0.
Preparation of standard stock solution of MGN
10mg of MGN was precisely weighed and dispensed to100ml volumetric flask containing few ml of mobile phase (Methanol 70: Water 30 at pH 5.0adjusted with OPA). The volume was made up to the mark using mobile phase slowly and from side to side mild wobbly to make up the substantial solution of 100μg/ml. This solution was ultrasonicated for 30min in three cycles each of 10 min. Furthermore, it was the filtered through 0.45μ membrane filter in order to take away minute particles if any.
Preparation of working solution of MGN
Aliquot of 1.0ml of standard stock solution of MGN was withdrawn by means of micropipette and diluted to 10.0ml with mobile phase (Methanol 70: Water 30 at pH 5.0adjusted with OPA) to make the resultant solution of 10μg/ml. This solution was ultra-sonicated for 30 min in three cycles each of 10 min. Also, it was then filtered through 0.45μ membrane syringe filter and filled in HPLC vials for injection. This solution was then used for supplementary study.
Selection of mobile phase
To begin with mobile phase composition of Methanol: Water 50:50 was selected for RP-HPLC trial runs. The separation carried out on C18stationary phase (4.6mm x 250mm, 5µ particle size). The results obtained were evaluated for retention time, peak area, no. of theoretical plates and tailing factor. The conditions for trial runs were as given in Table 1 below.
An additional trial run was executed with composition of methanol: water in the ratio of 70:30 at pH 5.0 adjusted with OPA at flow rate of 1ml/min. The detector was set at 243nm. The chromatogram obtained was evaluated for retention time, peak area, no. of theoretical plates and tailing factor. 
System suitability testing
The system suitability testing was planned to ensure the consistency of the system for evaluation of MGN. The study was proposed with 10μg/ml working solution as prepared in process written in section 6.2.1.4. This solution was injected to set chromatographic conditions as given in Table 3 . to evidence the chromatogram for MGN. The following chromatogram was integrated to get retention time, peak area, tailing factor and number of theoretical plates for MGN. 
HPLC method validation
Linearity and Range: Volume of standard stock solution (100μg/ml)of MGN equivalent to 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0ml was pipette out using micro-pipette and transferred to six different 10ml volumetric flasks. The aliquot of each volumetric flask was diluted up to 10ml using the mobile phase to attain the consequent solutions of 10, 20, 30, 40, 50, and 60μg/mlin that order. Each of this solution was injected to the given chromatographic conditions and chromatograms were recorded. The same function was persistent three times for all standard solutions prepared to study linearity.
Precision: Precision of the method was studied at three points across the range for MGN. This was performed by setting three quality control standards for MGN in the given series of 10 to 60μg/ml. Precision experiment was performed to study two dissimilar parameters viz. repeatability and intermediate precision.
Accuracy: % Accuracy was determined from the particulars obtained for precision study. At this point it was determined from the observations of mean peak area obtained in the case of three QC standards of MGN defined for precision study.
Robustness:
In Robustness, the system parameters like organic concentration of the mobile phase (Methanol) and flow rate were varied as per Table 10 & 11 The 10μg/ml concentration standard solution of MGN was selected for this study and it was kept constant throughout all system parameters varied. The preferred concentration (10μg/ml) was injected to given chromatographic conditions three times at each level of change and chromatograms recorded. From the chromatograms acquired mean peak area was determined in all measurements made.
%Recovery:
 Preparation of stock from API:
10mg of MGN (API) was precisely weighed and transferred to 100ml volumetric flask containing few ml of mobile phase and volume was made up to the mark (100ml) using mobile phase (Methanol 70: Water 30 at pH 5.0adjusted with OPA) to obtain final concentration standard stock solution of MGN 100μg/ml. The following solution was filtered through 0.45μ membrane filter and ultra-sonicated for 30 min in three cycles each of 10 min.
 Preparation of standard stock solution from dosage form
Twenty tablets (Label claim 50mg of Mirabegron (OAB-F) Alembic Pharmaceuticals ltd) were weighed, triturated to obtain powder and average weight of powder was determined. Powder equivalent to 10mg was transferred to 100ml of mobile phase to attain the main stock solution of MGN100μg/ml. The substantial solution was filtered through 0.45μ membrane filter and ultra-sonicated for 30min in three cycles each of 10 min. From the main stock sample solution of MGN aliquots of 0.8, 1.0 and 1.2ml were pipette out using micro pipette in three different 10ml volumetric flasks and the solution of each of these flasks was diluted up to 10ml using mobile phase to obtain resultant sample solutions of 8, 10, 12μg/ml respectively.
 Preparation of test solution for % recovery by spike method
10μg/ml solution (prepared previously) of MGN (API) was spiked into each of above sample solutions of MGN viz. 8, 10 and 12μg/ml to obtain test solutions at 80%, 100% and 120%likewise. Each of these three level test solutions of MGN was injected in triplicate to the given chromatographic conditions and mean peak area for each level was determined.
Limit of Detection (LOD) and Limit of Quantitation (LOQ):
The LOD and LOQ were calculated from the slope(s) of the calibration plot and the standard deviation (SD) of thepeak areas using the formulae LOD = 3.3 σ/s and LOQ = 10σ/s. The results were given in Table
RESULTS AND DISCUSSION
Results of system suitability study are summarized in Table 1 . Six consecutive injections of the Standard solution showed uniform retention time, theoretical plate count, tailing factor and resolution For both the drugs which indicate a good system for analysis. 
SUMMARY AND CONCLUSION
The proposed study was planned to develop RP-HPLC method for quantitative estimation of Mirabegron (MGN) as API and to ascertain its application for estimation of MGN in finished product formulation (marketed tablet dosage form). We have fruitfully developed the RP-HPLC method estimation of MGN as API. The chromatographic conditions found an appropriate for the projected method were as herein below. Also, the system was found to be an appropriate with the following chromatographic conditions. The developed and optimized method was then subjected to method validation as per ICH Q2R1 guideline for the parameters like linearity, range, precision, accuracy, robustness, detection limit, quantitation limit etc. The linearity was established by measuring a series of standard solutions of MGN and found in the range of 10-60μg/ml. The calibration curve developed suggested linear relationship amongst concentration of MGN and observed response (mean peak area for MGN) with correlation coefficient of 0.9991. The regression equation obtained was y = 28712x -9335.7.
Precision of the method was studied at three levels across the range observed in linearity study. Three QC standards were defined viz. 15, 35 and 55μg/ml for this study. Precision was performed to ascertain the repeatability and intermediate precision. The results obtained showed %RSD for repeatability and intermediate precision were in the range of 0.65 to 1.96 and 0.92 to 1.90in that order. Results observed for %RSD in both (repeatability and intermediate precision) cases were less than 2%, hence, the method was found to be precise. % Accuracy was determined from the data of precision study indicated the %assay in the range of 92.26 to 98.54% w/w of MGN.
The robustness of the method was studied by purposeful difference in method parameters like organic concentration (Methanol) and flow rate. The results observed for organic concentration variation and flow rate change were in the The applicability of the method was studied in tablet dosage form of Mirabegron. The results obtained for percent recovery study were in the range of 101.52 to 104.65% w/w for MGN. The results obtained in conformity with the prescribed limits for MGN. In addition, absence of an additional peak (s) in this study indicated that the method was specific for the determination of MGN in capsule dosage form.
Detection and quantitation limit were determined from the standard error of calibration curve of MGN and found to be 2.07 and 6.28μg/ml respectively. From the lower values of detection limit it was observed that method was responsive for determination of MGN.
